Arcus Biosciences, Inc. RCUS · Stock Open Arcus Biosciences, Inc. in new tab
Arcus Biosciences, Inc. Analysis (RCUS)
Is Arcus Biosciences, Inc. a good investment? Arcus Biosciences, Inc. (RCUS) is currently trading at 27.62 USD. Market analysts have a consensus price target of 36.83 USD. This suggests a potential upside from current levels.
Earnings Schedule: Arcus Biosciences, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -3.10.
Investor FAQ
Does Arcus Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Arcus Biosciences, Inc.?
Arcus Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -3.38.
Company Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Community Discussion